GMP Products

Vecura has served as contract manufacturer for more than 10 years and has supplied cGMP grade gene therapy vectors for more than 20 clinical trials in different countries in Europe. More than 300 patients have been treated with vectors produced by Vecura. No adverse effects have been recorded. Vecura has a highly qualified staff consisting of physicians, molecular biologists, cell biologists and engineers. With our broad knowledge and long experience we have the possibility to develop tailor-made production processes according to the customers special demands. Vecura is approved by the Swedish Medical Products Agency as a manufacturer of cell- and gene therapy products for clinical trials.

References

An academic centre for gene therapy research and clinical grade manufacturing capability. Islam et al (1997) Ann Med 29, 579-583.

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Calarota et al (2001) Hum Gene Ther. Sep 1;12(13):1623-37.

Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Sylvèn et al, Coron Artery Dis. (2001) 12,239-43.

Effects of Intramyocardial Injection of phVEGF-A165 as Sole Therapy in Patients with Refractory Coronary Artery Disease – 12-month follow-up: Angiogenic gene therapy. Sarkar et al, Journal of Internal Medicine (2001) 250, 373-381.

Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Calarota et al, (1998) Lancet. May 2;351(9112):1320-5.

Vecura
Gene Therapy Center, CRC, Huddinge University Hospital,
SE-141 87 Stockholm, Sweden
Tel +46 8 58 58 38 43,
Fax +46 8 58 58 38 45
info@vecura.com

Updated: Tuesday, April 5, 2005 21:11